Application of aryloxycyclohexyl compounds in the preparation of anti-prostate cancer drugs
By developing aryloxycyclohexyl compounds, regulating androgen receptor activity and inhibiting AR/ARV7 protein, the problem of treatment of metastatic castration-resistant prostate cancer in the prior art has been solved, and effective treatment of a variety of prostate cancers has been achieved. Especially the treatment of metastatic castration-resistant prostate cancer.
Patent Information
- Application Number
- CN202310419880.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-04-14
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2043-04-14
AI Technical Summary
The prior art is difficult to effectively treat metastatic castration-resistant prostate cancer (mCRPC), especially after endocrine therapy, androgen receptor (AR) mutations occur, causing the disease to progress to castration-resistant and lack of effective cure options.
An aryloxycyclohexyl compound was developed to prepare anti-prostate cancer drugs, inhibit nuclear transport of AR by regulating androgen receptor (AR) activity, blocking the interaction between AR and DNA, and demonstrating AR/ARV7 Protein degradation activity, used to treat a variety of prostate cancers, including metastatic castration-resistant prostate cancer.
The compounds showed significant anti-prostate tumor activity, able to selectively regulate AR activity, inhibit tumor cell proliferation, and demonstrated concentration-dependent anti-tumor effects in in vitro and in vivo experiments, providing a resistant prostate cancer to metastatic castration. Treatment plan.
Smart Images

Figure BDA0004186462380000011 
Figure BDA0004186462380000021 
Figure BDA0004186462380000031
Abstract
Description
Technical Field
[0001] The present invention generally relates to aryloxycyclohexyl related compounds and their use in preparing drugs for various indications. In particular, the present invention relates to aryloxycyclohexyl compounds having halogenated phenyl and / or pyridazine carboxylic acid substituent groups and their use in treating various cancers. Background Art
[0002] Prostate cancer is an androgen-dependent tumor, androgen can stimulate the growth of prostate cancer cells and disease progression. Endocrine therapy is one of the conventional treatment methods. For example, the standard of treatment for advanced PCa is mainly androgen deprivation therapy (ADT), such as surgical castration (bilateral orchiectomy) / drug castration (such as injection of Noradrena). ADT therapy has a significant effect in the early stage of treatment, but as the disease progresses, the androgen receptor (AR) mutates, and the mutated AR is more sensitive to low levels of androgens, thereby driving the disease to castration-resistant prostate cancer (CRPC). Almost all patients with advanced prostate cancer will eventually progress to CRPC after receiving endocrine therapy. In addition, up to 30% of prostate cancer patients will transform into metastatic castration-resistant prostate cancer (mCRPC) within 10 years of initial treatment. At present, patients diagnosed with early focal prostate cancer are usually cured clinically, but patients diagnosed with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) have no cure options in clinical practice. Summary of the invention
[0003] In order to solve the above technical problems, the present invention provides the use of aryloxycyclohexyl compounds in preparing anti-prostate cancer drugs. Among them, the aryloxycyclohexyl compound is a compound represented by formula (I), a pharmaceutically acceptable salt, stereoisomer or deuterated product thereof:
[0004]
[0005]
[0006] Furthermore, the pharmacological test of the present invention shows that the aryloxycyclohexyl compound of the present invention has anti-prostate tumor activity. The aryloxycyclohexyl compound of the present invention is used for preparing drugs for treating various cancers. For example, prostate cancer, including but not limited to primary / localized prostate (newly diagnosed), locally advanced prostate cancer, recurrent prostate cancer, metastatic prostate cancer, metastatic castration-resistant prostate cancer (mCRPC) and hormone-sensitive prostate cancer.
[0007] Instruction Manual
[0008] Figure 1 for the proliferation activity of prostate cancer cells LNCaP and 22RV1; Figure 2 for antitumor activity in nude mice; Figure 3 AR / ARV7 protein degradation activity. DETAILED DESCRIPTION
[0009] The present invention is further described below in conjunction with specific embodiments and test examples, but the scope of the present invention is not limited in any form.
[0010] Example 1 Synthesis of Compound 1
[0011]
[0012] 1. Add K2CO3 (28.0 g, 202.0 mmol, 3.5 eq) to a solution of A1 (10.0 g, 58.0 mmol, 1 eq) and 4-piperidinemethanol (13.4 g, 114.0 mmol, 2 eq) in acetonitrile (120 mL), and then stir at 60 ° C overnight. After the reaction is completed, filter, concentrate the filtrate, extract the synthetic oily crude with ethyl acetate (200 mL × 2), and wash the combined organic layers with water (200 mL × 2) and brine (200 mL × 2). Dry with Na2SO4 and concentrate to obtain a white solid A2 (10.0 g, 68.5%). 1 HNMR (300MHz, DMSO-d6): δ7.82(d,J=9.6Hz,1H),7.29(d,J=9.6Hz,1H),4.58-4.53(m,3H),3 .89(s,3H),3.32-3.29(m,2H),3.03(t,J=12.3Hz,2H),1.82-1.79(m,3H),1.23-1.15(m,2H).
[0013] 2. Add TBSCl (8.95 g, 59.7 mmol, 1.5 eq) and imidazole (3.57 g, 51.7 mmol, 1.3 eq) to a DMF (200 mL) solution containing A2 (10.0 g, 39.8 mmol, 1.0 eq) and stir at room temperature for 4 hours. Concentrate to remove the solvent. The resulting oil is extracted with ethyl acetate (300 mL × 2). The combined organic layers are washed with water (300 mL) and brine (200 mL × 2). Dry and concentrate with Na2SO4, and the resulting residue is purified by column chromatography (EA / PE = 1 / 3, v / v) to obtain yellow oil A3 (10.0 g, 68.8%).
[0014] 3. A3 (5 g, 13.7 mmol, 1.0 eq) was dissolved in MeOH (50 mL), and a solution of NaOH (820 mg, 20.5 mmol, 1.5 eq) in water (20 mL) was added and mixed, and then stirred at room temperature overnight. The reaction mixture was acidified to pH 7 with 1N HCl, and then extracted with ethyl acetate (100 mL × 2). The combined organic layers were washed with water (100 mL × 2), dried over Na2SO4 and concentrated to obtain a yellow solid A4 (3.5 g, 72.9%)
[0015] 4. At 0°C, add NaH (60%, 5.8 g, 144.0 mmol, 1.5 eq) to a DMF (150 mL) solution containing trans-4-Boc-aminocyclohexanol (24.9 g, 115 mmol, 1.2 eq) in portions. After addition, stir at room temperature for 30 minutes, then recool to 0°C with an ice bath. Add B1 (15.0 g, 96.7 mmol, 1.0 eq) in portions. Stir the reaction mixture at room temperature for 4 hours. Concentrate the reaction mixture and extract the crude extract with ethyl acetate (300 mL × 2). Wash the combined organic layer with water (300 mL × 2), dry and concentrate with Na2SO4, and the crude extract is purified by chromatography (EA / PE = 1 / 4, v / v) to obtain a yellow solid B2 (19.0 g, 56.2%). 1 H NMR (300MHz, DMSO-d6): δ7.86 (d, J=8.7Hz, 1H), 7.40 (s, 1H), 7.13 (d, J=7.8Hz, 1H), 6.90-6.88 (m, 1H), 4. 55-4.48(m,1H),3.32-3.29(m,1H),2.05-2.01(m,2H),1.85-1.82(m,2H).1.51-1.41(m,4H),1.40(s,9H).
[0016] 5. B2 (6.0 g, 17.1 mmol) was dissolved in 100 mL of 4N HCl / dioxane solution. The reaction mixture was stirred at room temperature overnight. The solvent was removed by concentration. The white solid product B3 (5.5 g, excess 100%) was synthesized and used in the next step without further purification.
[0017] 6. Add HATU (6.92 g, 18.2 mmol, 2.0 eq) and DIPEA (6.92 g, 27.3 mmol, 3.0 eq) to a solution of A4 (3.2 g, 9.1 mmol, 1 eq) and B3 (4.0 g, 14.0 mmol, 1.5 eq) in THF (100 mL). The reaction mixture was stirred at room temperature for 4 h. After concentration, the crude extract was extracted with ethyl acetate (100 mL × 2). The combined organic layer was washed with water (100 mL × 2), dried over Na2SO4 and concentrated. The crude extract was subjected to column chromatography (EA / PE = 1 / 4 to 1 / 2, v / v) to obtain a white solid B4 (5.0 g, 94.3%). 1 H NMR (400MHz, DMSO-d6): δ8.55(d,J=8.0Hz,1H),7.83(d,J=8.4Hz,1H),7.77(d,J=9.6Hz,1 H),7.36(d,J=2.4Hz,1H),7.30(d,J=10.0Hz,1H),7.11(dd,J1=8.8Hz,J2=2.4Hz,1H),4.5 3-4.46(m,3H),3.85-3.81(m,1H),3.43(d,J=5.6Hz,2H),2.99-2.93(m,2H),2.09-2.07(m ,2H).1.88-1.86(m,2H),1.78-1.71(m,3H),1.66-1.47(m,4H),0.83(s,9H),0.01(s,6H).
[0018] 7. B4 (5.4 g, 9.2 mmol) and tetrabutylammonium fluoride trihydrate (3.48 g, 11.0 mmol) were dissolved in THF (100 mL) and stirred at 45 °C for 2 h. The mixture was poured into a saturated aqueous solution of NaCl and NH4Cl and extracted with EA. The combined organic layer was dried and concentrated. The crude extract was purified by flash chromatography with PE containing 80% EA to obtain a white solid B5 (3.9 g, 88% yield).
[0019] 8. Add Dess-Martin reagent (1.22 g, 2.8 mmol) to a solution of B5 (1.15 g, 2.4 mmol) in DCM (30 mL) at room temperature. The reaction mixture was stirred at room temperature for 1.5 h. TLC analysis showed that the starting material had been consumed. The mixture was then washed with saturated NaHCO3, sodium thiosulfate and brine. The organic layer was dried and concentrated, and the residue B9 (1.3 g, purity 80%) was used directly in the next step.
[0020] 9. A mixed solution of 1-1 (5.0 g, 25.8 mmol, 1.0 eq), Cs2CO3 (25.0 g, 77.4 mmol, 3.0 eq) and 1,2-dibromoethane (97 g, 516 mmol, 20 eq) in acetonitrile (20 mL) was stirred at 80°C for 16 hours. The mixture was extracted with DCM and concentrated, and purified by flash column chromatography (PE / DCM=10 / 1, v / v) to give 1-2 (2.8 g, 36%) as a yellow oil.
[0021] 10. A mixed solution of 1-2 (2.8 g, 9.36 mol, 1.0 eq), N-cbz-piperazine (2.9 g, 14.05 mmol, 1.5 eq) and K2CO3 (3.9 g, 28.08 mol, 3.0 eq) in acetonitrile (50 mL) was stirred at room temperature for 16 hours. The mixture was concentrated, and the residue was extracted with DCM, washed with brine, dried and concentrated with Na2SO4. Purification by flash column chromatography (PE / EA=5 / 1, v / v) gave 1-3 (2.3 g, 52.3%) as a yellow oil.
[0022] 11. At 0°C, add H2O2 (2.0 g, 104 mmol, 20.0 eq) to a solution of 1-3 (2.3 g, 5.2 mmol, 1.0 eq) in EA / AcOH (50 mL / 5 mL). Then stir at room temperature for 3 h. Pour the mixture into a saturated aqueous NaHCO3 solution, extract with DCM, wash with dichloromethane, dry and concentrate with Na2SO4. Purify with flash column chromatography (DCM / MeOH=15 / 1, v / v) to obtain a yellow solid 1-4 (1.5 g, 63%).
[0023] 12. A solution of 1-4 (1.5 g, 3.3 mmol, 1 eq) and Pd / C (3.0 g) in MeOH (20 mL) was stirred at room temperature under H2 for 16 hours. The mixture was filtered through a layer of Celite. The filtrate was concentrated to give 1-5 (900 mg, 82%) as a yellow oil.
[0024] 13, 1-5 (550 mg, 1.6 mmol) and B6 (1.1 g, 2.5 mmol, 1.5 eq) were dissolved in MeOH / DCM (2 mL / 20 mL), and then a catalytic amount of acetic acid was added at room temperature. Stirred at 0 ° C for 1 h. Then NaBH3CN (122 mg, 3.2 mmol, 2.0 eq) was added and stirred for 3 h. Then concentrated and purified by flash column chromatography (DCM / MeOH=10 / 1, v / v) to obtain a crude product, which was further purified by preparative high performance liquid chromatography to obtain a white solid compound 1. 1H NMR (400MHz, DMSO-d6): δ8.57(d,J=8.4Hz,1H),7.85(d,J=8.8Hz,1H),7.79(d,J=9.6Hz,1H),7.37(d,J =8.8Hz,1H),7.31(d,J=8.8Hz,1H),7.13(dd,J=2.4,8.8Hz,1H),4.56-4.44(m,3H),3.87-3.84(m,1H),3 .03-2.88(m,4H),2.83-2.75(m,2H),2.73-2.51(m,3H),2.46-2.33(m,8H),2.14-2.09(m,4H),1.98-1. 89(m,5H),1.82(d,J=8.8Hz,2H),1.78-1.62(m,2H),1.59-1.41(m,2H),1.24(s,1H),1.13-1.04(m,2H).
[0025] Example 2 Synthesis of Compound 2
[0026]
[0027] 1. At room temperature, add B6 (1.1 g, 2.4 mmol), N-Boc-piperazine (0.67 g, 3.6 mmol) and 3 drops of acetic acid, a methanol (3 mL) solution of sodium cyanoborohydride (0.3 g, 4.8 mmol) to dichloromethane (30 mL). Then stir at room temperature for 2 hours. Pour the mixture into a saturated aqueous sodium bicarbonate solution and extract with dichloromethane. Dry and concentrate the combined organic layer. Purify by flash chromatography (DCM / MeOH=20 / 1, v / v) to obtain a white solid 2-1 (1.2 g, 75%). MSm / z(ESI):638.3[M+1] + .
[0028] 2. Mix a solution of 2-1 (1.2 g, 1.9 mmol) in dioxane (10 mL) and methanol (10 mL) at room temperature, and add a solution of 4M HCl in dioxane (30 mL). Stir for 2 h at room temperature under N2. Then concentrate the mixture to dryness. The resulting crude extract is used directly in the next step. MS m / z (ESI): 538.2 [M+1] + .
[0029] 3. At room temperature and N2, a DMF (10 mL) solution of 2-2 (500 mg, 0.82 mmol), 4,4,5,5,5-pentafluoropentyl methanesulfonate (630 mg, 2.46 mmol) and K2CO3 (680 mg, 4.92 mmol) was stirred for 24 hours. The mixture was then poured into water and extracted with EA. The combined organic layer was dried and concentrated. The crude extract was purified by flash chromatography with 100% EA-10% MeOH in DCM to obtain a yellow solid, which was further purified by pre-HPLC to obtain a white solid, compound 2 (75 mg, 13%). 1 H NMR (400MHz, DMSO-d6): δ8.57(d,1H),7.85(d,1H),7.79(d,1H),7.38(d,1H),7.31(d,1H),7.14(dd,1H),4.5 6-4.52(m,1H),3.87-3.83(m,1H),2.99(t,2H),2.36-2.08(m,15H),1.91-1.49(m,12H),1.10-0.85(m,2H).MS m / z(ESI):698.4[M+1] + .
[0030] Example 3 Synthesis of Compound 3
[0031]
[0032] 1. At room temperature and N2, a DMF (20 mL) solution of 2-2 (600 mg, 0.98 mmol), 1-bromo-5-fluoropentane (500 mg, 2.95 mmol), CsI (39 mg, 0.1 mmol) and K2CO3 (1.35 g, 9.8 mmol) was stirred overnight. The mixture was then poured into water and extracted with ethyl acetate. The combined organic layer was dried and concentrated. Flash chromatography with 0-10% methanol in dichloromethane gave compound 3 (230 mg, 38%) as an off-white solid. 1 H NMR (400MHz, DMSO-d6): δ8.57(d,1H),7.85(d,1H),7.79(d,1H),7.38(d,1H),7.31(d,1H),7.14(dd,1H),4.56-4.44(m,4H ),4.37(t,1H),3.87-3.82(m,1H),2.99(t,2H),2.37(br,8H),2.20-2.09(m,4H),1.91-1.25(m,17H),1.08-1.02(m,2H).MS m / z(ESI):626.4[M+1] + .
[0033] Example 4 Synthesis of Compound 4
[0034]
[0035] 1. At room temperature, add B6 (500 mg, 1.07 mmol), 1-(3-fluoropropyl)azetidin-3-amine hydrochloride (329 mg, 1.60 mmol), KOAc (314 mg, 3.21 mmol) and 3 drops of acetic acid, a methanol (2 mL) solution of sodium cyanoborohydride (134 mg, 2.14 mmol) to a dichloromethane (20 mL) solution. After stirring at room temperature for 2 h, the mixture was poured into a saturated aqueous sodium bicarbonate solution and extracted with DCM. The combined organic layer was dried and concentrated. The crude extract was purified by flash chromatography to obtain a solid, which was further purified by preparative high performance liquid chromatography to obtain a white solid as compound 4 (120 mg, 19%). 1 HNMR (400MHz, DMSO-d6): δ8.57(d,1H),7.85(d,1H),7.79(d,1H),7.38(d,1H ),7.31(d,1H),7.14(dd,1H),4.56-4.45(m,4H),4.38(t,1H),3.90-3.82(m,1 H),3.56-3.52(m,2H),3.33-3.26(m,2H),2.98(t,2H),2.77(t,2H),2.53-5.5 1(m,2H),2.35(d,2H),2.10(d,2H),1.91-1.43(m,11H),1.08-1.02(m,2H).MS m / z(ESI):584.3[M+1] + .
[0036] Example 5 Synthesis of Compound 5
[0037]
[0038] 1. At room temperature, acetic acid (1.5 mL) was added to a solution of N-cbz-piperazine (4.50 g, 26.31 mmol) and 1-Boc-3-azetidinone (5.26 g, 23.92 mmol) in methanol (100 mL) and stirred for 1 hour. Then NaBH3CN (4.52 g, 71.76 mmol) was added. The resulting mixture was stirred at room temperature for 16 hours. The mixture was poured into a saturated aqueous NaHCO3 solution, extracted with EA, and the combined organic layer was dried and concentrated. 5-2 (4.75 g, 53%) was obtained by rapid chromatography with petroleum ether containing 25% EA as a colorless oil.
[0039] 2. At room temperature, add a solution of 5-2 in methanol (5 mL) to a solution of 4M HCl in dioxane (30 mL). Stir at room temperature for 2 h, then concentrate to dryness under reduced pressure. The resulting solid is 5-3 hydrochloride (3.7 g, crude extract), which is used directly in the next step.
[0040] 3. A mixture of 5-3 hydrochloride (3.7 g, 10.63 mmol), 1-fluoro-3-iodopropane (4.0 g, 21.26 mmol) and K2CO3 (7.33 g, 53.15 mmol) was stirred in a round-bottom flask at room temperature for 3 h. The mixture was then poured into water and extracted with ethyl acetate. The combined organic layers were dried over Na2SO4, filtered and concentrated. 5-4 (750 mg, 21%) was purified by flash chromatography using dichloromethane containing 6% methanol to obtain a light yellow oil.
[0041] 4. At room temperature, add 3 ml 4M HCl in dichloromethane and 500 mg 10% palladium on carbon to a solution of 5-4 (750 mg, 2.24 mmol) in methanol (50 mL). Then stir at room temperature under H2 for 16 hours. Then filter the mixture through a layer of Celite. Concentrate the filtrate to dryness. The resulting extract is used directly in the next step.
[0042] 5. At room temperature, B6 (660 mg, 1.41 mmol), 5-5 (657 mg, 2.11 mmol), KOAc (554 mg, 5.64 mmol) and 3 drops of acetic acid, sodium cyanoborohydride (177 mg, 2.82 mmol) in methanol (4 mL) were added to a dichloromethane (20 mL) solution. After stirring at room temperature for 2 h, the mixture was poured into a saturated aqueous NaHCO3 solution and extracted with dichloromethane. The mixed organic layers were dried and concentrated. The obtained extract was purified by flash chromatography to obtain a solid, which was further purified by preparative high performance liquid chromatography to obtain a white solid as compound 5 (230 mg, 25%). 1H NMR (400MHz, DMSO-d6): δ8.57(d,1H),7.85(d,1H),7.79(d,1H),7.38(d,1H) ,7.31(d,1H),7.14(dd,1H),4.56-4.44(m,4H),4.37(t,1H),3.87-3.83(m,1H ),3.36-3.31(m,1H),2.99(t,2H),2.83-2.78(m,1H),2.70(t,2H),2.44-2.09 (m,14H),2.35(d,2H),2.10(d,2H),1.91-1.46(m,12H),1.08-1.01(m,2H).MS m / z(ESI):653.4[M+1] + .
[0043] Example 6 Synthesis of Compound 6
[0044]
[0045] 1. At 25°C N2, DIEA (8.87 g, 68.6 mmol, 11.9 mL, 2.00 eq) was added to a mixture of compound B3 (8.60 g, 34.3 mmol, 1.00 eq), 6-chloropyridazine-3-carboxylic acid (5.98 g, 37.7 mmol, 1.10 eq), EDCI (7.89 g, 41.1 mmol, 1.20 eq) and HOBt (4.63 g, 34.3 mmol, 1.00 eq) in dichloromethane (86.0 mL) at once. The mixture was stirred at 25°C for 16 hours. Thin layer chromatography (petroleum ether: ethyl acetate = 1:1, R f =0.41) indicated that reactant 1 was completely consumed. The reaction mixture was filtered and concentrated. The residue was poured into 100 ml of water. The aqueous phase was extracted with dichloromethane (50.0 mL*4). The combined organic phase was washed with saturated citric acid aqueous solution (100 ml*3) and saturated sodium bicarbonate aqueous solution (100 mL*3). The combined organic phase was then washed with brine (10.0 mL), dried over anhydrous Na2SO4, and concentrated by vacuum filtration. The crude product was titrated with MTBE (50.0 mL) for 3 hours. A purple solid compound 6-1 (6.00 g, 15.3 mmol, yield 44.7%, purity 100%) was obtained. 1HNMR(400MHz,DMSO-d6)δ1.50-1.60(m,2H)1.65-1.73(m,2H)2.17-2.26(m,4H)4.03-4.16(m,1H)4.35(tt,J=9.93,3 .76Hz,1H)6.86(dd,J=8.68,2.45Hz,1H)7.01(d,J=2.32Hz,1H)7.57(d,J=8.80Hz,1H)7.71(d,J=8.80Hz,1H)7.98(br d, J = 7.95 Hz, 1H) 8.29 (d, J = 8.80 Hz, 1H). 2. Add 40 mL of n-butanol, compound 6-1 (2.60 g, 6.65 mmol, 1.00 eq), diisopropylethylamine (2.58 g, 19.9 mmol, 3.47 mL, 3 eq), and compound 3-[(piperidin-4-yl)methyl]azetidine-1-carboxylic acid tert-butyl ester (3.72 g, 14.6 mmol, 2.2 eq) to a 250 mL three-necked flask, heat to 120 ° C, and react for 16 hours. The reaction solution was cooled, filtered, and the filtered solid was collected. The filtered solid was slurried with 30 mL of ethyl acetate to obtain compound 6-2 (white solid, 3.55 g, purity: 95.6%). MS (ESI) m / z: 609.3 [M+H] + .
[0046] 3. Add 30mL of dichloromethane, compound 6-2 (3.55g, 5.83mmol, 1eq), and trifluoroacetic acid (6.64g, 58.3mmol, 4.31mL, 10eq) to a 250mL single-mouth bottle in sequence and react at 20°C for 1 hour. After detection, the reaction was not complete, and trifluoroacetic acid (1.99g, 17.5mmol, 1.29mL, 3eq) was added and reacted at 20°C for 1 hour. The reaction solution was concentrated to dryness, washed with 30mL of dichloromethane and continued to concentrate to obtain compound 6-3 (yellow oil, 6.89g, purity: 99%, 6TFA). MS (ESI) m / z: 509.3 [M+H] + .
[0047] 4. 10 mL of N, N-dimethylformamide, compound 6-3 (2.20 g, 1.84 mmol, 1 eq, 6 TFA), potassium carbonate (2.04 g, 14.75 mmol, 8 eq), and compound 4,4,5,5,5-pentafluoropentyl methane sulfonate (708 mg, 2.77 mmol, 1.5 eq) were added to a 250 mL single-mouth bottle in sequence and reacted at 20°C for 56 hours. The reaction solution was poured into water and extracted with ethyl acetate three times, 50 mL each time. The organic phases were combined, dried, filtered, and concentrated to obtain a crude product, which was purified by preparative separation to obtain compound 6 (white solid, 225 mg, purity: 99.2%).1 HNMR (400MHz, CDCl3) δ7.96(d,J=6.8Hz,1H),7.85(d,J=8.0Hz,1H),7.54(d,J=8.8Hz,1H),6.99(d,J= 2.4Hz,1H),6.94(d,J=9.6Hz,1H),6.93-6.83(m,1H),4.48-4.45(m,2H),4.43-4.28(m,1H),4.05-4.01 (m,1H),3.51-3.47(m,2H),3.01-2.98(m,2H),2.73-2.69(m,2H),2.48-2.44(m,3H),2.40-2.15(m,2H) ,2.00-2.15(m,1H),1.77-1.46(m,8H),1.26-1.21(m,4H),0.87-0.83(m,1H).MS(ESI)m / z:669.5[M+H] + .
[0048] Example 7 Synthesis of Compound 7
[0049]
[0050] 1. Add 50mL N,N-dimethylformamide, compound 6-3 (4.59g, 3.85mmol, 1.00eq, 6TFA), diisopropylethylamine (3.98g, 30.7mmol, 5.36mL, 8.00eq), and compound 3-fluoro-1-iodopropane (723mg, 3.85mmol, 1eq) to a 250mL single-mouth bottle in sequence and react at 20°C for 48 hours. Pour the reaction solution into water and extract with ethyl acetate three times, 50mL each time. Combine the organic phases, dry them, filter them, and concentrate them to obtain a crude product. The crude product is purified by preparative separation to obtain compound 7 (white solid, 225mg, purity: 99.6%). 1HNMR (400MHz, CDCl3) δ7.94 (d, J = 9.63Hz, 1H), 7.86 (br d,J=8.13Hz,1H),7.55(d,J=8.63Hz,1H),6.90-7.03(m,2H),6.85(dd,J=8.63,2.00Hz,1H),4.37-4.59(m,4H),4.31(br t,J=9.88Hz,1H),3.96-4.11(m,1H),3.52(br t,J=7.00Hz,2H),3.52(t,J=7.00Hz,2H),2.98(br t,J=12.1Hz,2H),2.74(t,J=7.00Hz,2H),2.49-2.65(m,3H),2.17(br s,4H),1.62-1.83(m,7H),1.39-1.53(m,4H),1.21-1.28(m,3H),0.86(br d,J=9.01Hz,1H).MS(ESI)m / z:569.5[M+H] + .
[0051] Example 8 Synthesis of Compound 8
[0052]
[0053] 1. Add 100 mL of dichloromethane and compound 8-1 (10.0 mg, 1.00 eq) in batches to peroxytrifluoroacetic acid (16.7 g, 1.40 eq), and heat in a 250 mL three-necked flask at 25°C for 1 hour. Add 100 mL of water and extract twice with dichloromethane, 50 mL each time. Wash the organic phase with brine, dry, and concentrate to obtain a crude product. The crude product is purified by column chromatography to obtain compound 8-2 (yellow oil, 13.0 g, yield: 82.3%, purity: 98.0%).
[0054] 2. Add nitric acid (5.22 g, 65.0% purity, 1.00 eq) in batches to 150 mL of trifluoroacetic acid and compound 8-2 (14.6 mg, 1.00 eq) at -30 °C, and keep warm at 25 °C for 3 hours. Add 500 mL of ice water, adjust the pH to 8 with sodium carbonate, and extract with ethyl acetate three times, 100 mL each time. Wash the organic phase with brine, dry, and concentrate to obtain compound 8-3 (yellow oil, 21.0 g, crude product). MS (ESI) m / z: 317.1 [M+H] + .
[0055] 3. Add 300 mL of ethanol, compound 8-3 (21.0 mg, 1.00 eq), 100 mL of water, and ammonium chloride (17.7 mg, 5.00 eq) into a 500 mL three-necked flask, add iron powder (18.5 g, 5.00 eq) to the reaction solution at 75 °C, and keep the reaction at 75 °C for 2 hours. Filter, and concentrate the filtrate under reduced pressure to obtain a crude product. The crude product was purified by preparative separation to obtain compound 8-4 (yellow oil, 5.79 g, yield: 28.6%, purity: 94.0%). MS (ESI) m / z: 287.0 [M+H] + .
[0056] 4. Dissolve compound 8-4 (3.90 g, 1.00 eq) in 115 mL of dichloromethane, add compound 1-Boc-3-azetidinone (3.50 g, 1.50 eq) and acetic acid (81.8 mg, 77.9 uL, 0.10 eq). After 15 minutes, add sodium triacetoxyborohydride (8.66 g, 3.00 eq) and stir at 25 ° C for 16 hours. After the reaction is complete, add water, extract with dichloromethane, dry, concentrate and spin dry to obtain crude compound 8-5 (red solid, 10.6 g, crude product). MS (ESI) m / z: 342.0 [M+H-100] + .
[0057] 5. Dissolve compound 8-5 (6.01 g, 13.6 mmol, 1.00 eq) in 150 mL of methanol and add HCl / MeOH (4.00 M, 34.0 mL, 10.0 eq). Stir at 25 °C for 1.5 hours. After the reaction is complete, adjust the pH to 7-8 with sodium bicarbonate aqueous solution, extract with dichloromethane, dry, concentrate and spin dry to obtain compound 8-6 (yellow oil, 3.74 g, yield: 64.3%, purity: 80.0%). MS (ESI) m / z: 342.0 [M+H] + .
[0058] 6. Add compound 8-6 (3.74 g, 1.00 eq) to 50 mL DMF, add DIPEA (2.83 g, 3.82 mL, 2.00 eq) and compound 3-fluoro-1-iodopropane (3.09 g, 1.50 eq), and stir at 25 ° C for 16 hours. After the reaction is completed, pour the reaction solution into 150 mL of water, extract with ethyl acetate, dry, concentrate, and spin dry to obtain a crude product. The crude product is purified by column chromatography to obtain compound 8-7. (Red oil, 1.25 g, yield: 25.4%, purity: 89.5%). MS (ESI) m / z: 402.0 [M + H] + .
[0059] 7. Dissolve compound 8-7 (1.25 g, 3.11 mmol, 1.00 eq) in 10 mL of methanol, add potassium carbonate (860 mg, 6.23 mmol, 2.00 eq) dissolved in 5 mL of water, and stir at 25 ° C for 16 hours. After the reaction is completed, directly concentrate and dry to obtain compound 8-8 (yellow oil, 681 mg, crude product). MS (ESI) m / z: 306.0 [M+H] + .
[0060] 8. Dissolve compound 6-1 (738 mg, 1.89 mmol, 1.00 eq) in 5 mL of n-butanol, add DIEA (731 mg, 5.66 mmol, 985 uL, 3.00 eq) and 8-8 (576 mg, 1.89 mmol, 1.00 eq), and stir at 80 ° C for 16 hours. After the reaction, add water, extract with ethyl acetate, concentrate the organic phase and spin dry to obtain a crude product. The crude product was purified by preparative separation to obtain compound 8 (white solid, 330 mg, yield: 26.2%, purity: 99.0%). 1 H NMR (400MHz, DMSO-d6): δ8.56(d,J=8.25Hz,1H),7.85(d,J=8.76Hz,1H),7.78( d,J=9.51Hz,1H),7.38(d,J=2.38Hz,1H),7.30(d,J=9.63Hz,1H),7.13(dd,J=8. 82,2.44Hz,1H),6.88(d,J=8.38Hz,2H),6.43(d,J=8.38Hz,2H),5.80(d,J=6.8 8Hz,1H),4.35-4.59(m,5H),3.78-3.95(m,2H),3.62(t,J=6.88Hz,2H),2.93(br t,J=11.7Hz,2H),2.72(t,J=6.88Hz,2H),2.46(t,J=7.00Hz,2H),2.36(br d,J=6.88Hz,2H),2.05-2.17(m,2H),1.89(br d,J=9.88Hz,2H),1.58-1.81(m,7H),1.42-1.57(m,2H),1.05-1.19(m,2H).MS(ESI)m / z:331.3[M+H] + .
[0061] Example 9 Synthesis of Compound 9
[0062]
[0063] 1. Add dichloromethane (120 mL), compound 1-Boc-piperidine-4-carboxaldehyde (5.30 g, 1.00 eq), compound 1-(4-bromophenyl)piperazine (5.99 g, 1.00 eq), and glacial acetic acid (149 mg, 0.10 eq) to a 500 mL three-necked flask in sequence, stir for 15 minutes, add NaBH(OAc)3 (15.8 g, 3.00 eq), and stir at 25°C for 1 hour. Monitor the reaction, compound 20 is not completely reacted, add compound 1-Boc-piperidine-4-carboxaldehyde (5.30 g, 1.00 eq), NaBH(OAc)3 (7.90 g, 1.50 eq) to the reaction solution, and stir at 25°C for 3 hours. After the reaction is complete, add 100 mL of aqueous solution to the reaction solution, and extract with dichloromethane three times, 100 mL each time. The organic phases were combined, washed twice with saturated brine, 50 mL each time, dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product. The crude product was purified by column chromatography to obtain compound 9-2 (red solid, 13.5 g, crude product). MS (ESI) m / z: 438 [M+H] + .
[0064] 2. Add 50 mL of N, N-dimethylformamide, compound 9-2 (3.00 g, 6.84 mmol, 1.00 eq), and compound methyl acrylate (8.09 g, 93.9 mmol, 8.46 mL, 13.7 eq) into a 100 mL three-necked flask, add palladium acetate (153 mg, 684 umol, 0.10 eq), potassium carbonate (2.84 g, 20.5 mmol, 3.00 eq), tri(o-methylphenyl)phosphine (416 mg, 1.37 mmol, 0.20 eq), protect with nitrogen, and react at 110 ° C for 16 hours. The reaction solution was added with 100 mL of water, extracted with ethyl acetate (100 mL x 2), washed with 50 mL of brine, separated, the organic phase was dried, filtered and the filtrate was concentrated to obtain a crude product, which was purified by preparative separation to obtain compound 9-3 (light green solid, 1.16 g, yield: 36.5%, purity: 93.3%). MS: (ESI) m / z: 444 [M+H] + .
[0065] 3. Add 15 mL of dichloromethane and compound 9-3 (1.35 g, 3.04 mmol, 1.00 eq) to a 100 mL single-mouth bottle, add trifluoroacetic acid (6.16 g, 54.0 mmol, 4.00 mL, 17.7 eq), and react at room temperature for 2 hours. Concentrate the mixture under reduced pressure, add 25 mL of dichloromethane, and concentrate under reduced pressure. Repeat 3 times to obtain compound 9-4 (yellow oil, 2.95 g). MS: (ESI) m / z: 344 [M+H] + .
[0066] 4. Add 20 mL of n-butanol and compound 9-4 (2.94 g, 3.22 mmol, 0.9 eq, 5 TFA) to a 100 mL three-necked flask, add N, N-diisopropylethylamine (3.70 g, 28.6 mmol, 4.99 mL, 8.00 eq), compound 6-1 (11.4 g, 3.58 mmol, 1.00 eq), and react at 90 ° C for 48 hours. Add 80 mL of water to the reaction solution, extract with ethyl acetate (80 mL x 3), wash with 50 mL of brine, separate the liquids, dry the organic phase, filter and concentrate the filtrate to obtain a crude product. The crude product was purified by column chromatography to obtain compound 9-5 (yellow solid, 900 mg, yield: 26.9%, purity: 74.8%). 1 H NMR: 400MHz, CDCl3, δ=7.97 (d, J=9.63Hz, 1H), 7.86 (d, J=8.13Hz, 1H), 7.52-7.66 (m, 2H), 7. 43(d,J=8.76Hz,2H),6.95-7.02(m,2H),6.82-6.91(m,3H),6.27(d,J=15.8Hz,1H),4.51(br d,J=13.2Hz,2H),4.25-4.39(m,1H),3.99-4.12(m,1H),3.78(s,3H),3.30(brs,4H),3.05(brt,J=12.0Hz,2H),2.58(brs,4 H),2.09-2.38(m,6H),1.87-2.02(m,3H),1.62-1.76(m,3H),1.39-1.51(m,2H),1.20-1.36(m,2H).MS:(ESI)m / z:698[M+H] + .
[0067] 5. Add 6 mL of ethanol and compound 9-5 (560 mg, 802 umol, 1.00 eq) to a 50 mL single-mouth bottle, add sodium hydroxide (2M, 1.40 mL, 3.50 eq), and react at 70 ° C for 16 hours. Filter the mixture, wash the filter cake with 1 mL of water, dissolve the filter cake with 20 mL of N, N-dimethylformamide, and add 2 mL of HCl (2M) to adjust the pH to acidic. The mixed solution was purified by preparative separation to obtain compound 9 (white solid, 250 mg, yield: 71.3%, purity: 99.8%). 1H NMR(400MHz,DMSO-d6)δ10.81(br s,1H),8.63(d,J=8.13Hz,1H),7.79-7.97(m,2H),7.59(d,J=8.76Hz,2H),7.47-7.55(m,2H),7.36-7.42(m,1H) ,7.14(dd,J=8.76,2.38Hz,1H),7.03(d,J=8.76Hz,2H),6.35(d,J=16.01Hz,1H),4.42-4.60(m,3H),3.97-4.16( m,4H),3.58(brs,1H),3.41(m,2H),3.01-3.20(m,6H),2.27(brs,1H),2.11(d,J=9.38Hz,2H),2.00(d,J=11.1H z,2H),1.90(d,J=10.4Hz,2H),1.59-1.72(m,2H),1.43-1.58(m,2H),1.20-1.36(m,2H).MS:(ESI)m / z:684[M+H] + .
[0068] Example 10 Synthesis of Compound 10
[0069]
[0070] 1. Anhydrous toluene (50 mL), compound 9-2 (1.50 g, 1.00 eq), compound 1-(3-fluoropropyl)azetidin-3-amine (678 mg, 1.50 eq), cesium carbonate (3.34 g, 3.00 eq), RockPhos Pd G3 (143 mg, 0.05 eq) were added to a 250 mL three-necked flask in sequence, and stirred at 110 ° C for 16 hours. After the reaction was complete, the reaction solution was concentrated under reduced pressure to obtain a crude product. The crude product was purified by column chromatography to obtain compound 10-1 (brown oil, 13.5 g, purity: 92.4%, yield: 55.1%). MS (ESI) m / z: 698 [M+H] + .
[0071] 2. Anhydrous methanol (10 mL), compound 10-1 (890 mg, 1.00 eq), and methanol hydrochloride (7.50 mL, 4.0 M, 15.5 eq) were added to a 100 mL three-necked flask in sequence and stirred at 25 ° C for 2.5 hours. After the reaction was complete, the reaction solution was concentrated to dryness, and the crude product was adjusted to pH 8 with a saturated sodium carbonate aqueous solution and then freeze-dried. The freeze-dried crude product was slurried with 50 mL of dichloromethane, filtered, and the filtrate was concentrated to dryness to obtain a crude compound 10-2 (yellow solid, 370 mg, purity: 91.8%, yield: 47.9%). MS (ESI) m / z: 390 [M+H] + .
[0072] 3. Add n-BuOH (10 mL), compound 10-2 (370 mg, 1.00 eq), compound 6-1 (445 mg, 1.20 eq), and DIPEA (368 mg, 3.00 eq) to a 100 mL three-necked flask in sequence, and stir at 60 ° C for 56 hours. Add 30 mL of aqueous solution to the reaction solution, and extract twice with ethyl acetate, 50 mL each time. Combine the organic phases, wash the organic phase with saturated brine twice, 50 mL each time, dry over anhydrous sodium sulfate, filter, and concentrate to obtain a crude product. The crude product was purified by preparative separation to obtain compound 10 (white solid, 205 mg, purity: 99.6%, yield: 28.8%). 1 H NMR (400MHz, CDCl3) δ7.97(d,J=9.51Hz,1H),7.88(d,J=8.13Hz,1H),7.57(d,J=8.63Hz,1H),6.95-7.02(m,2H), 6.82-6.88(m,3H),6.54(d,J=8.76Hz,2H),4.48-4.60(m,3H),4.45(d,J=5.88Hz,1H),4.25-4.40(m,1H),4.00-4 .19(m,2H),3.83(m,2H),2.97-3.11(m,8H),2.70(m,2H),2.28(d,J=6.75Hz,2H),2.18(m,J=10.51=Hz,5H),1.76 -1.90(m,4H),1.62-1.72(m,2H),1.38-1.52(m,3H),1.26-1.33(m,2H),0.77-0.94(m,1H).MS(ESI)m / z:744[M+H] + .
[0073] Example 11 Synthesis of Compound 11
[0074]
[0075] 1. Add 30 mL of acetonitrile and compound 8-4 (1.89 g, 6.60 mmol, 1.00 eq) to a 100 mL three-necked flask, and then add compound 1-bromo-5-fluoropentane (1.12 g, 6.60 mmol, 1 eq) and potassium carbonate (1.82 g, 13.2 mmol, 2 eq). React at 80 °C for 16 hours. The reaction solution is concentrated to obtain a crude product, which is then purified by column chromatography to obtain compound 11-1 (yellow oil, 865 mg, yield: 32.5%, purity: 93.0%). MS: (ESI) m / z: 375 [M+H] + .
[0076] 2. Add 10 mL of methanol and compound 11-1 (865 mg, 2.31 mmol, 1.00 eq) to a 100 mL three-necked flask, dissolve potassium carbonate (638 mg, 4.62 mmol, 2 eq) in 5 mL of water, add to the reaction solution, and react at room temperature for 12 hours. Concentrate to remove methanol from the reaction solution, add 30 mL of dichloromethane for extraction, separate the liquids, dry the organic phase, and concentrate to obtain compound 11-2 (white solid, 752 mg).
[0077] 3. Add 10 mL of n-butanol and compound 11-2 (722 mg, 2.59 mmol, 1.00 eq) to a 50 mL three-necked flask, add N,N-diisopropylethylamine (1.01 g, 7.78 mmol, 1.36 mL, 3.00 eq) and compound 6-1 (1.02 g, 2.59 mmol, 1 eq), and react at 80 degrees Celsius for 16 hours. Add 30 mL of water to the reaction solution, extract with ethyl acetate (30 mL x 3), wash with 30 mL of brine, separate the liquids, dry the organic phase, filter and concentrate the filtrate to obtain a crude product. The crude product was prepared by reverse reaction to obtain compound 11 (white solid, 700 mg, yield: 41.3%, purity: 96.2%). 1HNMR: 400MHz, DMSO-d6, δ = 8.55 (d, J = 8.13Hz, 1H), 7.85 (d, J = 8.76Hz, 1H), 7.78 (d, J = 9.51Hz, 1H), 7.38 (d, J = 2 .38Hz,1H),7.30(d,J=9.63Hz,1H),7.13(dd,J=8.82,2.44Hz,1H),6.87(d,J=8.25Hz,2H),6.48(d,J=8.38Hz, 2H),5.27-5.37(m,1H),4.33-4.58(m,5H),3.77-3.94(m,1H),2.86-3.03(m,4H),2.36(brd,J=6.88Hz,2H),2. 10(d,J=10.51Hz,2H),1.89(d,J=9.76Hz,2H),1.40-1.80(m,13H),1.04-1.19(m,2H).MS:(ESI)m / z:633[M+H] + .
[0078] Example 12 Synthesis of Compound 12
[0079]
[0080] 1. At 25°C, 4-aminophenylboronic acid pinacol ester (3.36 mg, 15.3 mmol, 1.20 eq), Pd(dppf)Cl2 (935 mg, 1.28 mmol, 0.10 eq) and K2CO3 (3.53 g, 5.11 mmol, 2.00 eq) were added to a solution of dioxane (50.0 mL) and water (5.00 mL) containing compound 6-1 (5.00 g, 12.8 mmol, 1.00 eq). The mixture was stirred at 80°C for 16 hours. LCMS and thin layer chromatography (petroleum ether / ethyl acetate = 1:1, Rf = 0.36) showed that compound 6-1 was completely consumed. The reaction mixture was washed with water (50.0 mL), extracted with ethyl acetate (80 mL*2), and the combined organic phase was washed with brine (50.0 mL), dried over anhydrous Na2SO4, and concentrated by vacuum filtration. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 1 / 1 to 0 / 1) to obtain compound 12-1 (3.20 g, 7.14 mmol, yield 55.9%) as a yellow solid.
[0081] 2. Compound 12-1 (1.00 g, 2.23 mmol, 1.00 eq), compound 1-bromo-5-fluoropentane (566 mg, 3.35 mmol, 1.50 eq), K2CO3 (617 mg, 4.47 mmol, 2.00 eq) and KI (556 mg, 3.35 mmol, 1.50 eq) were mixed in a DMF (10.0 mL) solution, degassed with N2 for 3 times at 25 °C, and then stirred at 70 °C for 16 hours under N2 conditions. LCMS showed that compound 12-1 was completely consumed. Filter, and the filtrate was detected by HPLC. The filtrate was purified by preparative HPLC (column: Waters Xbridge BEH C18100*30 mm*10 um; mobile phase: [water(NH4HCO3)-ACN]; B%: 35%-65%, 8 min). Compound 12 (210 mg, 376 umol, yield 16.8%, purity 96.0%) was a white solid. 1 HNMR(400MHz,DMSO-d6)δ8.97(d,J=8.4Hz,1H),8.19(d,J=8.8Hz,1H),8.00 -8.08(m,3H),7.86(d,J=8.8Hz,1H),7.40(d,J=2.4Hz,1H),7.15(dd,J=2.4, 8.8Hz,1H),6.71(d,J=8.1Hz,2H),6.33(t,J=5.4Hz,1H),4.49-4.59(m,1H), 4.46(td,J=6.4,47.5Hz,2H),3.87-3.96(m,1H),3.02-3.21(m,2H),2.13(br d,J=10.4Hz,2H),1.93(br d,J=10.4Hz,2H),1.42-1.75(m,10H).
[0082] Example 13 Synthesis of Compound 13
[0083]
[0084] 1. Dissolve PPh3 (9.57 g, 36.5 mmol, 0.50 eq) in compound 13-1 (20.0 g, 73.0 mmol, 1.00 eq) and place in a 100 mL single-necked round-bottom flask. Stir and reflux at 120 ° C for 4 hours under N2 conditions. LCMS showed that PPh3 (9.57 g, 36.5 mmol, 0.50 eq) was completely consumed and a main peak of suitable mass was detected. The mixture was concentrated in vacuo. The crude product was titrated with TBME (10 mL) at 25 ° C. Compound 13-2 was a white solid with a yield of 40.9% (16.0 g, 29.8 mmol).1 HNMR (400MHz, DMSO-d6) δ7.97-7.78(m,15H), 4.11-3.89(m,2H), 2.65-2.52(m,2H).
[0085] 2. At -78°C, add n-BuLi (2.50M, 5.59mL, 1.50eq) to THF (10.0mL) containing compound 13-2 (5.00g, 9.32mmol, 1.00eq). Stir the mixture at -78°C for 1 hour. Then add a solution of THF (10.0mL) containing compound 1-Cbz-4-piperidinecarboxaldehyde (2.77g, 11.1mmol, 1.20eq) to the above mixture. Stir the resulting mixture at 25°C for 2 hours. Thin layer chromatography (petroleum ether / ethyl acetate = 5 / 1, R f =0.45) indicated that compound 13-2 (5.00 g, 9.32 mmol, 1.00 eq) was completely consumed and a new spot was formed. The residue was poured into NH4Cl (30.0 mL). The aqueous phase was extracted with ethyl acetate (15.0 mL×3). The combined organic phase was washed with 50.0 mL of brine, dried over anhydrous Na2SO4, and concentrated by vacuum filtration. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate=5 / 1). Compound 13-3 was obtained as a yellow oil (1.50 g, 3.98 mmol, yield 42.6%). 1 HNMR(400MHz,DMSO-d6)δ7.46-7.16(m,5H),5.58(br t,J=10.3Hz,1H),5.32(td,J=7.4,10.7Hz,1H),5.07(s,2H),3.99(br d,J=13.1Hz,2H),3.08(dt,J=7.4,18.7Hz,2H),2.96-2.74(m,2H),2.64-2.52(m,1H),1.50(brd,J=11.2Hz,2H),1.20(dq,J=4.2,12.3Hz,2H).
[0086] 3. Under N2 conditions, Pd / C (1.70 g, 10% purity) was added to a THF (10.0 mL) solution containing compound 13-3 (1.50 g, 3.98 mmol, 1.00 eq). The suspension was degassed under vacuum and purged with H2 several times. The mixture was stirred at 25°C under H2 (15 psi) for 1 hour. Thin layer chromatography (petroleum ether: ethyl acetate = 3:1, R f =0.55) showed that compound 13-3 (1.50 g, 3.98 mmol, 1.00 eq) was completely consumed. Thin layer chromatography (dichloromethane: methanol = 5: 1, Rf =0.49) indicated the formation of a new spot. The mixture was filtered and concentrated in vacuo. The crude product was used directly in the next step without further purification. Compound 13-4 (0.7 g, 2.85 mmol, yield 71.81%) was a yellow oil.
[0087] 4. Add triethylamine (620 mg, 6.13 mmol, 853 uL, 1.50 eq) to an ethanol mixture (20.0 mL) containing compound 13-4 (1.00 g, 4.09 mmol, 1.00 eq) at 25°C. After the addition, add compound 6-1 (1.6 g, 4.09 mmol, 1.00 eq) to the mixture at 25°C. The mixture was stirred at 80°C under N2 for 16 hours. LC-MS and HPLC test results showed that compound 6-1 (1.60 g, 4.09 mmol, 1.00 eq) was completely consumed, and a main peak of suitable mass was detected. Filter and concentrate the mixture in vacuum. The crude product was purified by high performance liquid chromatography (column: Phenomenex C1880*40 mm*3 um; mobile phase: [water(NH4HCO3)-ACN]; B%: 50%-80%, 8 min). A white solid compound 13 (0.20 g, 343 umol, yield 8.40%, purity 100%) was obtained. 1 HNMR(400MHz,DMSO-d6)δ8.63-8.54(m,1H),7.90-7.74(m,2H),7.43-7.29(m,2 H),7.13(dd,J=2.4,8.8Hz,1H),4.60-4.40(m,3H),3.93-3.78(m,1H),2.98(br t,J=11.9Hz,2H),2.28-2.05(m,4H),1.94-1.84(m,2H),1.80-1.72(m,2H),1.69-1.45(m,7H),1.38-1.27(m,2H),1.18-1.05(m,2H).
[0088] Example 14 Synthesis of Compound 14
[0089]
[0090] 1. At 0°C, DAST (1.32 g, 8.22 mmol, 1.09 mL, 2.00 eq) was added dropwise to a solution of compound 14-1 (1.00 g, 4.11 mmol, 1.00 eq) in dichloromethane (10.0 mL). The reaction mixture was stirred at 25°C for 16 hours. Thin layer chromatography (petroleum ether: ethyl acetate = 10:1, Rf = 0.24) showed that compound 14-1 remained at 60%, and a major new spot was found. The reaction mixture was quenched with NaHCO3 (20.0 mL). The aqueous solution was extracted with DCM (30.0 mL*3), and the combined organic layers were dried over Na2SO4, filtered and concentrated under vacuum. Compound 14-2 (700 mg, 2.85 mmol, yield 69.4%, purity 100%) was a brown oil. 1HNMR(400MHz,CHLOROFORM-d)δ0.94-1.10(m,2H)1.17-1.33(m,3H)1.38(s,9H)1.52-1.72(m,4H)2.61(br t,J=12.10Hz,2H)4.01(br s,2H)4.31(t,J=6.14Hz,1H)4.42(t,J=6.14Hz,1H).
[0091] 2. At 25°C, add TFA (1.54 g, 13.5 mmol, 1.00 mL, 4.40 eq) to a solution of compound 14-2 (750 mg, 3.06 mmol, 1.00 eq) in dichloromethane (5.00 mL). The reaction mixture was stirred at 25°C for 30 min, and then subjected to thin layer chromatography (petroleum ether: ethyl acetate = 5:1, R f =0.31) indicated that compound 14-2 was completely consumed. The mixture was concentrated in vacuo. The crude product, compound 14-3, was a brown oil and was carried to the next step without further purification.
[0092] 3. At 25°C, add TEA (517 mg, 5.11 mmol, 5.00 eq) and compound 14-3 (530 mg, 2.04 mmol, 2.00 eq, TFA) to a solution of compound 6-1 (400 mg, 1.02 mmol, 1.00 eq) in EtOH (10.0 mL). Stir the mixture at 100°C for 16 hours. Thin layer chromatography (petroleum ether: ethyl acetate = 1:1, R f=0.66) indicated that compound 6 was completely consumed. The reaction mixture was concentrated under reduced pressure to remove ethanol (10.0 mL). The residue was diluted with ethyl acetate (10.0 mL) and rinsed with water (10.0 mL). The aqueous phase was extracted with ethyl acetate (5.00 mL*3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to obtain a crude product. The crude product was titrated with MTBE (5.00 mL) at 25°C for 60 min to obtain compound 14 as a yellow solid. 1 H NMR(400MHz, DMSO-d6)δ1.06-1.20(m,2H)1.25-1.36(m,2H)1.49-1.57(m,2H)1.59-1.81(m,7H)1.90(br d,J=10.15Hz,2H)2.11(br d,J=9.78Hz,2H)2.98(br t,J=11.80Hz,2H)3.80-3.95(m,1H)4.38(t,J=6.11Hz,1H)4.44-4.58(m,4H)7.14(dd,J=8.80,2.45Hz,1H)7.3 4(d,J=9.66Hz,1H)7.39(d,J=2.45Hz,1H)7.80(d,J=9.54Hz,1H)7.86(d,J=8.68Hz,1H)8.59(d,J=8.19Hz,1H).
[0093] Example 15 Synthesis of Compound 15
[0094]
[0095] 1. At 25°C, add AcOH (563 mg, 9.38 mmol, 536 uL, 1.00 eq) to a dichloromethane solution (120 mL) containing compound 12-1 (4.20 g, 9.38 mmol, 1.00 eq) and compound 1-Boc-3-azetidinone (4.20 mg, 24.5 mmol, 2.62 eq). The reaction mixture was stirred at 25°C for 1 hour. Then NaBH(OAc)3 (7.95 g, 37.5 mmol, 4.00 eq) was added at 25°C. The mixture was stirred at 25°C for 14 hours. LCMS (ET49637-14-p1a1) showed that compound 12-1 was completely consumed. Pour the reaction mixture into water (100 mL) and adjust to pH = 7 with NaHCO3. Extract with dichloromethane (50.0 mL*3). The combined organic layers were dried over Na2SO4, filtered and concentrated to give a residue. Compound 15-1 (1.40 g, 2.32 mmol, yield 24.8%) was a yellow solid.
[0096] 2. At 25°C, add TFA (3.23 g, 28.3 mmol, 2.10 mL, 13.1 eq) to a solution of compound 15-1 (1.30 g, 2.16 mmol, 1.00 eq) in dichloromethane (40.0 mL). Stir the mixture at 25°C for 15 hours. LCMS showed that compound 15-1 was completely consumed. Pour the reaction mixture into a NaHCO3 aqueous solution (50.0 mL) and stir. Filter the obtained suspension, wash with water (10.0 mL*2), and dry the filtered cake under vacuum to obtain the product. Compound 15-2 (900 mg, 1.79 mmol, yield 83.0%) was obtained as a yellow solid.
[0097] 3. At 25°C, DIEA (462 mg, 3.58 mmol, 623 uL, 2.00 eq) was added to a solution of compound 15-2 (900 mg, 1.79 mmol, 1.00 eq) in acetonitrile (10.0 mL). The mixture was stirred at 25°C for 16 hours. LCMS showed that compound 15-2 was completely consumed. The reaction mixture was reduced with MeCN using N2 and diluted with DMF (2.00 mL). The crude product of compound 15 (180 mg) was obtained as a pale yellow solid by high performance liquid chromatography (chromatographic column: Phenomenex Luna C1875*30mm*3um; mobile phase: water (FA)-ACN; B%: 20%-50%, 8 min), and further separated by SFC (chromatographic column: DAICEL CHIRALCELOJ (250mm*30mm, 10um); mobile phase: [0.1% NH3H2O MEOH]; B%: 70%-70%, 20 min). Compound 15 (100 mg, 175 umol, yield 9.82%, purity 98.9%) was a pale yellow solid. 1HNMR (400MHz, DMSO-d6) δ8.99(d,J=8.20Hz,1H),8.20(d,J=9.04Hz,1H),7.98-8.10(m,3H),7.86(d,J=8.68Hz,1H),7.40(d,J=2.44Hz,1H ),7.14(dd,J=8.88,2.38Hz,1H),6.61-6.78(m,3H),4.53(s,2H),4.41(s,1H),4.00-4.11(m,1H),3.84-3.99(m,1H),3.67(s,2H),3.31(br s,2H),2.81(s,2H),2.13(br d,J=10.5Hz,2H),1.87-1.99(m,2H),1.68(br s,6H)
[0098] Example 16 Synthesis of Compound 16
[0099]
[0100] 1. Add compound 4-(4-aminophenoxy)-1-piperidinic acid tert-butyl ester (1.90g, 1.00eq), compound 1-bromo-5-fluoropentane (1.10g, 1.00eq), and 20mL acetonitrile to a 100mL three-necked flask in sequence, heat the reaction solution to 85 degrees Celsius, and react for 12 hours. After the reaction is completed, cool the reaction system to room temperature, slowly add 20mL of water to the reaction solution at room temperature, and extract with dichloromethane three times, 20mL each time. After the organic phases are combined, they are washed with 100mL saturated sodium chloride aqueous solution, the organic phases are dried, and concentrated to obtain a crude compound 16-2. The crude product is separated and purified by preparative separation to obtain compound 16-2 (510mg, yield: 18.1%, purity: 88.0%, yellow oily liquid). 1 H NMR(400MHz,CHLOROFORM-d)δ=6.83-6.79(m,2H),6.60(d,J=8.8Hz,2H),4.52 (t,J=6.0Hz,1H),4.41(t,J=6.0Hz,1H),4.26(tt,J=3.5,7.3Hz,1H),3.76-3. 68(m,2H),3.31-3.23(m,2H),3.10(t,J=7.1Hz,2H),1.93-1.84(m,2H),1.81- 1.63(m,7H),1.58-1.50(m,2H),1.50-1.44(m,10H).MS(ESI)m / z=325.0[M+H] + .
[0101] 2. Dissolve compound 16-2 (500 mg, 1.00 eq) in 5 mL of ethyl acetate and add to a 100 mL three-necked flask. Slowly add HCl / EtOAc (4 M, 5 mL, 15.2 eq) to the reaction solution. The reaction solution is reacted at 20 degrees Celsius for 12 hours. After the reaction is completed, the reaction solution is concentrated to dryness to obtain a crude compound 16-3 (520 mg, hydrochloride, pink solid). MS (ESI) m / z = 281.0 [M+H] + .
[0102] 3. Compound 16-3 (470 mg, 1.00 eq, hydrochloride), compound 6-1 (580 mg, 1.00 eq), 15 mL DMSO, and K2CO3 (410 mg, 2.00 eq) were added to a 100 mL three-necked flask in sequence, and the reaction solution was heated to 100 degrees Celsius for 12 hours. After the reaction was completed, the reaction system was cooled to room temperature, 50 mL of water was slowly added to the reaction solution at room temperature, and extracted with ethyl acetate three times, 30 mL each time. After the organic phases were combined, they were washed with saturated sodium chloride aqueous solution three times, 30 mL each time, and the organic phases were dried and concentrated to obtain a crude compound 16. The crude product was separated and purified by preparative separation to obtain compound 16 (210 mg, yield: 21.3%, purity: 95.5%, white solid). 1 H NMR (400MHz, DMSO) δ8.62 (d, J=8.1Hz, 1H), 7.84 (dd, J=9.2, 11.3Hz, 2H), 7.41-7.36 (m, 2H),7.13(dd,J=2.4,8.8Hz,1H),6.78(d,J=8.9Hz,2H),6.51(d,J=8.9Hz,2H),5.17(br s,1H),4.58-4.47(m,2H),4.44-4.36(m,2H),4.12-4.03(m,2H),3.92-3.80(m,1H),3.60- 3.51(m,2H),2.99-2.91(m,2H),2.14-2.07(m,2H),2.01-1.86(m,4H),1.73-1.39(m,12H).
[0103] Example 17 Synthesis of Compound 17
[0104]
[0105] 1. Dissolve compound 4-fluoromethylpiperidine (500 mg, 1.00 eq), compound 6-1 (196 mg, 1.00 eq, HCl), and DIEA (3.71 g, 5 mL, 22.4 eq) in 5 mL DMSO, heat the reaction solution to 100 degrees and stir for 4 hours, combine multiple batches, add 70 mL of water to the reaction solution, and extract twice with ethyl acetate, 100 mL each time. The organic phases are combined and washed with 50 mL of saturated sodium chloride aqueous solution, the organic phases are dried, and concentrated to obtain a crude product. The crude product is purified by preparative separation to obtain compound 17 (356 mg, yield: 58.4%, purity: 99.0%, brown solid). 1HNMR(400MHz,CHLOROFORM-d)δ7.99(d,J=9.5Hz,1H),7.87(br d,J=8.1Hz,1H),7.57(d,J=8.8Hz,1H),7.03-6.97(m,2H),6.86(dd,J=2.4,8.8Hz,1H),4.57(d,J=13.5Hz,2H),4.43-4.23(m,3H), 4.12-3.99(m,1H),3.08(dt,J=2.4,12.9Hz,2H),2.23-2.04(m,5H),1.90(d,J=13.0Hz,2H),1.74-1.64(m,2H),1.52-1.36(m,4H).
[0106] Example 18 Synthesis of Compound 18
[0107]
[0108] 1. Anhydrous dichloromethane (40 mL), compound 1-Cbz-4-piperidone (4.01 g, 1.00 eq), compound 18-1 (2.58 g, 1.05 eq, hydrochloride), and ZnCl2 (2.34 g, 1.00 eq) were added to a 250 mL three-necked flask in sequence and stirred at 20° C. for 12 hours. NaBH(OAc)3 (5.45 g, 1.50 eq) was added to the reaction solution and stirred at 20° C. for 6 hours. After the reaction was complete, the reaction solution was concentrated to dryness to obtain a crude product. The crude product was purified by preparative separation to obtain compound 18-2 (brown oil, 1.70 g, yield: 30.6%). 1 HNMR(400MHz, CDCl3)δ7.42-7.31(m,4H),7.44-7.28(m,1H),5.13(s,2H),4.09(s,2H),3.06-2.91(m,4H),2.8 0(s,2H),2.29(dt,J=7.3,14.5Hz,3H),1.81(d,J=8.4Hz,2H),1.46(d,J=9.9Hz,2H).MS(ESI)m / z:325.1[M+H] + .
[0109] 2. Methanol (10 mL), compound 18-2 (1.20 g, 1.00 eq), and Pd / C (240 mg, 1.00 eq) were added to a 100 mL hydrogenation bottle in sequence, and stirred at 20°C and 30 Psi for 12 hours under a hydrogen atmosphere. After the reaction was complete, the reaction solution was filtered and the filtrate was concentrated to dryness to obtain a crude compound 18-3 (white solid, 700 mg, yield: 99.5%). 1HNMR (400MHz, DMSO-d6) δ2.99-2.84(m,4H),2.70(t,J=6.9Hz,2H),2.53-2.48(m,2H),2.27-2.11(m,3H),1.79-1.69(m,2H),1.32-1.20(m,2H).
[0110] 3. DMSO (5 mL), compound 18-3 (309 mg, 1.00 eq), DIEA (204 mg, 2.00 eq), and compound 6-1 (150 mg, 1.00 eq) were added to a 100 mL three-necked flask in sequence and stirred at 100 ° C for 12 hours. After the reaction was complete, 50 mL of water was added to the reaction solution, and the mixture was extracted twice with ethyl acetate, 20 mL each time, and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to obtain a crude product, which was purified by preparative separation to obtain compound 18 (off-white solid, 215 mg, yield: 49.5%). 1 H NMR (400MHz, DMSO-d6) δ8.60(d,J=8.3Hz,1H),7.83(dd,J=9.2,17.2Hz,2H),7.42-7.32(m,2H),7.13(dd,J=2.4,8.8Hz,1H),4.57-4.48(m,1H),4.33(br d,J=13.4Hz,2H),3.92-3.80(m,1H),3.19-3.07(m,2H),2.95(t,J=13.8Hz,2H),2.7 5(t,J=7.0Hz,2H),2.46-2.38(m,1H),2.28-2.16(m,2H),2.14-2.06(m,2H),1.89(br d,J=12.8Hz,4H),1.69-1.58(m,2H),1.56-1.45(m,2H),1.43-1.31(m,2H).MS(ESI)m / z:545[M+H] +
[0111] Example 19 Synthesis of Compound 19
[0112]
[0113] 1. DMSO (5 ml), compound 19-1 (300 mg, 1.00 eq), DIEA (198 mg, 2.00 eq), and compound 6-1 (157 mg, 767 umol, 1.00 eq) were added to a 50 mL single-mouth bottle in sequence and stirred at 100 degrees for 12 hours. The reaction solution was filtered, and the filtrate was purified by preparative separation to obtain compound 19 (milky white solid, 330 mg, yield: 76.2%, purity: 99%).1 H NMR (400MHz, DMSO-d6) δ8.60 (d, J=8.3Hz, 1H), 7.83 (dd, J=9.2, 19.3Hz, 2H), 7.45-7. 26(m,2H),7.13(dd,J=2.4,8.8Hz,1H),4.59-4.42(m,3H),3.91-3.76(m,1H),2.98(br t,J=11.8Hz,2H),2.76-2.68(m,1H),2.59(br t,J=5.3Hz,4H),2.17-2.05(m,2H),1.97-1.79(m,8H),1.69-1.58(m,2H),1.56-1.38(m,4H).MS(ESI)m / z=559.2[M+OH] + .
[0114] Example 20 Synthesis of Compound 20
[0115]
[0116] 1. Dissolve compound 1-Boc-piperazine (240 mg, 1.00 eq) and compound 6-1 (504 mg, 1.00 eq) in 5 mL DMSO, add K2CO3 (356 mg, 2.00 eq) to the reaction solution, and stir at 100°C for 12 hours. Add 50 mL of water to the reaction solution and extract three times with ethyl acetate, 30 mL each time. The organic phases are combined and washed with 60 mL of saturated sodium chloride aqueous solution, the organic phases are dried, and concentrated to obtain a crude product. The crude product is separated and purified by preparative separation to obtain compound 20-1 (140 mg, yield: 19.4%, purity: 96.7%, yellow solid). MS (ESI) m / z: 541.2 [M+H] + .
[0117] 2. Dissolve compound 20-1 (140 mg, 1.00 eq) in 1 mL of ethyl acetate, add HCl / EtOAc (4M, 2 mL, 30.9 eq) to the reaction solution at 0°C, stir at 20°C for 12 hours, and detect that the raw material remains. Add HCl / EtOAc (4M, 2 mL, 30.9 eq) to the reaction solution, heat the reaction solution to 35°C and stir for 2 hours. Concentrate the reaction solution directly to dryness to obtain the crude product 20-2, which is directly used in the next step (140 mg, yield: 75.9%, purity: 67.0%, white solid, hydrochloride). MS (ESI) m / z: 441.2 [M+H] + .
[0118] 3. Compound 20-2 (120 mg, 1.00 eq) and compound 3-fluoro-1-iodopropane (76.7 mg, 1.50 eq) were dissolved in 3 mL DMF, and DIEA (70.3 mg, 2.00 eq) was added dropwise under nitrogen. The reaction solution was stirred at 20 ° C for 16 hours, 40 mL of water was added to the reaction solution, and extracted with ethyl acetate three times, 10 mL each time. The organic phases were combined and washed with 20 mL of saturated sodium chloride aqueous solution, the organic phases were dried, and concentrated to obtain a crude product. The crude product was purified by preparative separation to obtain compound 20 (30.0 mg, yield: 22.0%, purity: 100%, white solid). 1H NMR(400MHz,DMSO-d6)δ8.69(br d,J=8.1Hz,1H),7.92(dd,J=5.6,9.0Hz,2H),7.48-7.40(m,2H),7.23-7.17( m,1H),4.67-4.56(m,2H),4.53(t,J=5.9Hz,1H),3.99-3.88(m,1H),3.77(br s,4H),2.57(br d,J=4.4Hz,5H),2.18(d,J=10.1Hz,2H),2.02-1.86(m,5H),1.78-1.66(m,2H),1.64-1.53(m,2H).MS(ESI)m / z:501.2[M+H] + .
[0119] Example 21 Synthesis of Compound 21
[0120]
[0121] 1. Dissolve compound 21-1 (15.0 g, 1.00 eq) in 150 mL of dichloromethane, and add compound 1A (18.3 g, 1.20 eq), TEA (14.5 g, 1.80 eq), and DMAP (978 mg, 0.10 eq) to the reaction solution in sequence at 0 ° C. The reaction solution was heated to 25 ° C and stirred for 12 hours. 200 mL of water was added to the reaction solution, and extracted with dichloromethane three times, 50 mL each time. The organic phases were combined and washed with 100 mL of saturated sodium chloride aqueous solution, the organic phases were dried, and concentrated to obtain a crude product. The crude product was separated and purified by column chromatography to obtain a yellow oily substance as compound 21-2. 1H NMR (400MHz, CHLOROFORM-d) δ = 7.80 (d, J = 8.3Hz, 2H), 7.37 (d, J = 8.0Hz, 2H), 4.14 (d, J = 6.9Hz, 2H), 4.01-3. 93(m,2H),3.59(dd,J=5.2,8.9Hz,2H),2.97-2.78(m,1H),2.47(s,3H),1.42(s,9H).MS(ESI)m / z:286[M+H] + .
[0122] 2. Dissolve compound 21-2 (17.4 g, 1.00 eq) in TBAF (1 M, 174 mL, 3.71 eq), keep warm and stir at 70 ° C for 1 hour, add 500 mL of water to the reaction solution, extract with ethyl acetate three times, 200 mL each time. The organic phases are combined and washed with 200 mL of saturated sodium chloride aqueous solution, the organic phases are dried, and concentrated to obtain a crude product. The crude product is separated and purified by column chromatography to obtain compound 21-3 (7.50 g, yield: 77.7%, light yellow oil). 1 HNMR(400MHz,CHLOROFORM-d)δ4.58(d,J=6.0Hz,1H),4.47(d,J=6.1Hz,1H),4.06-3.97(m,2H),3.75 (dd,J=5.4,8.8Hz,2H),2.96-2.75(m,1H),1.44(s,9H),1.26(t,J=7.2Hz,1H).MS(ESI)m / z:406[M+H] + .
[0123] 3. Dissolve compound 21-3 (7.50 g, 1.00 eq) in 5 mL of ethyl acetate, add HCl / EtOAc (4 M, 40 mL, 4.04 eq) to the reaction solution, and stir the reaction solution at 15°C for 12 hours. The reaction solution is directly concentrated to dryness to obtain the crude product 21-4, which is used directly in the next step without treatment (5.36 g, crude, white oil, hydrochloride). 1 H NMR (400MHz, DMSO-d6) δ9.64-9.17(m,2H),4.64(d,J=5.3Hz,1H),4.52(d,J=5.1Hz,1H),3.98(br d,J=3.6Hz,2H),3.75(br dd,J=5.7,10.6Hz,2H),3.19-3.00(m,1H).
[0124] 4. Dissolve compound 6-1 (200 mg, 1.00 eq), compound 21-4 (45.5 mg, 0.71 eq, HCl), and K2CO3 (141 mg, 2.00 eq) in 10 mL DMSO, heat the reaction solution to 100 ° C and stir for 12 hours, add 100 mL of water to the reaction solution, and extract twice with ethyl acetate, 200 mL each time. The organic phases are combined and washed with 20 mL of saturated sodium chloride aqueous solution, the organic phases are dried, and concentrated to obtain a crude product. The crude product is purified by preparative separation to obtain compound 21 (26.0 mg, yield: 58.5%, purity: 95.0%, off-white solid). 1 H NMR(400MHz,CHLOROFORM-d)δ8.03(d,J=9.3Hz,1H),7.85(br d,J=8.0Hz,1H),7.57(d,J=8.6Hz,1H),7.01(d,J=2.4Hz,1H),6.86(dd,J=2.4, 8.8Hz,1H),6.65(d,J=9.3Hz,1H),4.73(d,J=5.4Hz,1H),4.61(d,J=5.4Hz,1H), 4.46-4.27(m,3H),4.18-3.98(m,3H),3.23(tddd,J=5.3,8.3,13.6,16Hz,1H), 2.30-2.07(m,4H),1.72-1.64(m,2H),1.53-1.41(m,3H).MS(ESI)m / z:444[M+H] + .
[0125] Example 22 Synthesis of Compound 22
[0126]
[0127] 1. Add 50mL of dichloromethane, compound 1-Cbz-4-piperidone (4.00g, 1.00eq), compound 21-4 (2.15g, 1.00eq), and ZnCl2 (2.34g, 1.00eq) to a 100mL single-mouth bottle in sequence and react at 15°C for 1 hour. Add NaBH(OAc)3 (3.63g, 1.00eq) to the reaction solution and react at 15°C for 12 hours. Add 50mL of water to the reaction solution and extract twice with dichloromethane, 100mL each time. Wash the organic phase with brine, dry, and concentrate to obtain a crude product. The crude product was purified by preparative separation to obtain compound 22-1 (white oil, 1.19g, yield: 19.4%, purity: 86%). 1H NMR(400MHz,CHLOROFORM-d)δ7.31-7.20(m,5H),4.49-4.34(m,2H),3.93(br s,2H),3.32(br t,J=7.3Hz,2H),2.96(t,J=6.9Hz,2H),2.88(t,J=11.2Hz,2H),2.81-2.67(m,1H ),2.21-2.08(m,1H),1.58(s,2H),1.16(d,J=8.8Hz,2H).MS(ESI)m / z:307[M+H] + .
[0128] 2. Add 15 mL of methanol, compound 22-1 (1.00 g, 1.00 eq), and Pd / C (150 mg, 10% purity) to a 75 mL hydrogenation bottle in sequence, react at 40 Psi and 30 ° C for 4 hours under a hydrogen atmosphere, filter the reaction solution and spin dry to obtain a crude product. The crude product was purified by preparative separation to obtain compound 22-2 (white solid, 526 mg, yield: 93.5%). 1 H NMR(400MHz,CHLOROFORM-d)δ4.55(d,J=5.5Hz,1H),4.43(d,J=5.6Hz,1H),3.36(t,J=7. 1Hz,2H),3.10(td,J=3.8,12.6Hz,2H),2.99(t,J=6.9Hz,2H),2.68-2.56(m,2H),2.36(br s,2H),2.19-2.06(m,1H),1.81-1.58(m,2H),1.24-1.10(m,2H).
[0129] 3. Add 3 mL of N,N-dimethylformamide, compound 6-1 (300 mg, 1.00 eq), compound 22-2 (132 mg, 1.00 eq), and DIEA (2.23 g, 22.4 eq) to a 10 mL thumb bottle in sequence, and stir at 100 °C for 12 hours under a nitrogen atmosphere. Add 20 mL of water to the reaction solution, extract twice with ethyl acetate, 20 mL each time, combine the organic phases, wash twice with saturated brine, dry over anhydrous sodium sulfate, filter, and concentrate to obtain a crude product. The crude product was purified by preparative separation to obtain compound 22 (white solid, 195 mg, yield: 47.2%, purity: 98.0%). 1H NMR (400MHz, DMSO-d6) δ8.59(d,J=8.3Hz,1H),7.85(d,J=8.8Hz,1H),7.80(d,J=9.5Hz,1H) ,7.39(d,J=2.4Hz,1H),7.33(d,J=9.6Hz,1H),7.13(dd,J=2.4,8.8Hz,1H),4.58-4.49(m,2 H),4.44(d,J=6.1Hz,1H),4.21-4.09(m,2H),3.92-3.79(m,1H),3.30-3.19(m,4H),2.91(t ,J=6.5Hz,2H),2.77-2.61(m,1H),2.31(td,J=4.0,7.8Hz,1H),2.16-2.06(m,2H),1.89(br d,J=10.4Hz,2H),1.75-1.44(m,6H),1.26-1.10(m,2H). MS(ESI)m / z:391[M-163+H] + .
[0130] Example 23 Synthesis of Compound 23
[0131]
[0132] 1. Add N,N-dimethylformamide (15mL), 8-4 (1.5g, 1.00eq), compound 1-iodopropane (1.34g, 1.50eq), and potassium carbonate (1.45g, 2.00eq) to a 100mL three-necked flask in sequence and protect with nitrogen. Keep warm at 25°C for 12 hours. Add 100mL of water to the reaction solution and extract twice with ethyl acetate, 200mL each time. Wash the organic phase with brine, dry, and concentrate to obtain a crude product. The crude product is purified by column chromatography to obtain compound 23-1 (yellow oil, 650mg, yield: 35.5%, purity: 94%). MS (ESI) m / z: 329 [M+H] + . 1H NMR(400MHz,CHLOROFORM-d)δ6.95(d,J=8.4Hz,2H),6.58(d,J=8.4Hz,2H),4.52(td,J=1.9,13.2Hz,1H),4.05-3.95(m,1H),3.93-3. 53(m,1H),3.13-3.03(m,3H),2.70(t,J=12.4Hz,1H),2.51-2.40(m,2H),1.87-1.54(m,6H),1.30-1.15(m,2H),1.01(t,J=7.4Hz,3H).
[0133] 2. Compound 23-1 (650 mg, 1.00 eq), potassium carbonate (547 mg, 2.00 eq), 10 mL methanol, and 1 mL water were added to a 100 mL three-necked flask in sequence and reacted at 15°C for 12 hours. After the reaction was completed, the mixture was concentrated to dryness to obtain compound 23-2 (white solid, 1.24 g, crude product).
[0134] 3. Add 6 mL of n-butanol, compound 6-1 (650 mg, 1.00 eq), compound 23-2 (386 mg, 1.00 eq), and DIEA (4.82 g, 22.4 eq) to a 50 mL single-mouth bottle. Keep warm at 80 °C for 12 hours. After spin drying, a crude product is obtained. 10 mL of water is added to the crude product, and it is extracted twice with ethyl acetate, 20 mL each time. The organic phase is washed with brine, dried, and concentrated to dryness to obtain a crude product. The crude product is purified by preparative separation to obtain compound 23 (white solid, 637 mg, yield: 62.6%, purity: 96%). 1HNMR (400MHz, DMSO-d6) δ8.58(d,J=8.3Hz,1H),7.85(d,J=8.8Hz,1H),7.78(d,J=9.5Hz,1H),7.39(d,J=2.3Hz,1H),7.31(d, J=9.6Hz,1H),7.13(dd,J=2.3,8.8Hz,1H),6.86(d,J=8.4Hz,2H),6.47(d,J=8.4Hz,2H),5.33(t,J=5.5Hz,1H),4.60-4.50(m, 1H),4.45(d,J=13.1Hz,2H),3.92-3.78(m,1H),2.98-2.88(m,4H),2.36(d,J=6.9Hz,2H),2.13-2.06(m,2H),1.89(d,J=10.5H z,2H),1.70-1.60(m,4H),1.53(qd,J=7.4,14.4Hz,5H),1.12(q,J=11.0Hz,2H),0.92(t,J=7.4Hz,3H).MS(ESI)m / z:587[M+H] + .
[0135] Example 24 Synthesis of Compound 24
[0136]
[0137] 1. Add N,N-dimethylformamide (15mL), 8-4 (1.5g, 1.00eq), compound 3-fluoro-1-iodopropane (1.5g, 1.50eq), and potassium carbonate (1.45g, 2.00eq) to a 100mL three-necked flask in sequence and protect with nitrogen. Keep warm at 25°C for 12 hours. Add 50mL of water to the reaction solution and extract twice with ethyl acetate, 100mL each time. Wash the organic phase with brine, dry, and concentrate to obtain a crude product. The crude product is purified by column chromatography to obtain compound 24-1 (yellow oil, 550mg, purity: 93%)
[0138] 2. Anhydrous methanol (3 mL), water (0.6 mL), compound 24-1 (780 mg, 1.00 eq), and K2CO3 (622 mg, 2.00 eq) were added to a 50 mL three-necked flask in sequence and stirred at 15 °C for 12 hours. After the reaction was complete, the reaction solution was concentrated to dryness to obtain crude compound 24-2 (bright yellow oil, 1.34 g). MS (ESI) m / z: 251 [M+H] + .
[0139] 2. Add dimethyl sulfoxide (2mL), compound 24-2 (400mg, 1.00eq), compound 6-1 (625mg, 1.00eq), DIEA (413mg, 2.00eq) to a 10mL single-mouth bottle in sequence, and stir at 130°C for 2 hours. After the reaction is complete, add 30mL of aqueous solution to the reaction solution, and extract with ethyl acetate three times, 20mL each time. Combine the organic phases, wash the organic phase with saturated brine twice, 50mL each time, dry over anhydrous sodium sulfate, filter and concentrate to obtain a crude product. The crude product was purified by preparative separation to obtain compound 24 (yellow solid, 402mg, purity: 98.9%, yield: 41.1%). 1 H NMR(400MHz,CHLOROFORM-d)δ7.95(d,J=9.6Hz,1H),7.87(br d,J=8.3Hz,1H),7.56(d,J=8.8Hz,1H),7.02-6.93(m,4H),6.86(dd,J=2.4,8.8Hz,1H),6.67(br d,J=8.1Hz,2H),4.65(t,J=5.6Hz,1H),4.45-4.44(m,1H),4.56-4.44(m, 3H),4.39-4.28(m,1H),4.12-3.99(m,1H),3.31(t,J=6.8Hz,2H),2.97(br t,J=11.9Hz,2H),2.48(d,J=6.5Hz,2H),2.18(t,J=10.6Hz,4H),2.12-1.97(m,2H),1.81(d,J =11.3Hz,3H),1.75-1.62(m,2H),1.52-1.40(m,2H),1.34-1.20(m,2H).MS(ESI)m / z:605[M+H] + .
[0140] Pharmacological experiments
[0141] Experimental Example 1 LNCaP and 22RV1 Cell Proliferation Antagonism Test
[0142] The cell proliferation detection kit (CCK-8) method was used to evaluate the in vitro antiproliferative effects of compounds 8 and 10 on LNCaP and 22RV1 cells. The experimental steps are as follows: LNCaP or 22RV1 cells (1×10^4 cells per well) were seeded in a 96-well plate in rmi-1640 medium supplemented with 10% fetal bovine serum. After incubation at 37°C for 24 hours, the cells were treated with different concentrations of compounds for 24 hours. Then 10μl of CCK8 solution was added to each well and incubated for another 2h. The absorbance at 450nm was measured using an enzyme reader (BioTek enzyme reader). The cell viability (%) calculation formula is: Cell viability (%) = (AS-Ab) (Ac-Ab) × 100, where AS, Ac, and Ab represent the absorbance of drug wells with different concentrations, control wells, and blank wells, respectively. The results of the cell proliferation antagonism test are shown in Figure 1 The above cell proliferation antagonism test results show that compounds 8 and 10 can effectively antagonize the proliferation of prostate cancer cells LNCaP and 22RV1.
[0143] Experimental Example 2 Antitumor Effect Test in Nude Mice
[0144] The 22RV1 tumor mass stored in the back of Babl / c nude mice was removed, minced, and inoculated subcutaneously in the back of Babl / c nude mice. 3 ~300mm 3 , the mice were randomly divided into groups according to the tumor volume and began to be dosed. A total of 5 experimental groups were set up, namely the solvent control group, and 2 compound 8 and compound 10 treatment groups, with 7 animals in each group. The drugs were dissolved in 10% ethanol + 10% polyoxyethylene castor oil + 80% 0.9% sodium chloride solvent. The solvent control group was intraperitoneally injected with an equal amount of solvent. The doses of compound 8 and compound 10 drug experimental groups were 10 mg / kg and 20 mg / kg, respectively, and the drug was administered once a day. The dosage was 10 mL / kg. The body weight was weighed every 3 days, and the length and width of the tumor were measured with a vernier caliper to calculate the tumor volume. The calculation formula was: Tumor volume = 1 / 2*tumor length * tumor width * tumor width. The animals were killed 22 days after administration, the tumor tissue was removed and weighed, and the tumor inhibition rate was calculated. The calculation formula was: Tumor inhibition rate % = tumor weight of treatment group / tumor weight of control group * 100%. The anti-tumor activity results are shown in Figure 2 The above in vivo antitumor activity results in nude mice showed that compounds 8 and 10 exhibited effective in vivo antitumor activity in a concentration-dependent manner.
[0145] In summary, the in vitro / in vivo data of the pharmacological test all show that the aryloxycyclohexyl compounds of the present invention have anti-prostate tumor activity, especially compounds 8 and 10 characterized by obvious anti-tumor activity, and have concentration dependence. The use of the aryloxycyclohexyl compounds of the present invention for preparing anti-tumor drugs can be used to treat a variety of cancers, such as prostate cancer, including but not limited to primary / localized prostate (newly diagnosed), locally advanced prostate cancer, recurrent prostate cancer, metastatic prostate cancer, metastatic castration-resistant prostate cancer (mCRPC) and hormone-sensitive prostate cancer. This is because the aryloxycyclohexyl compounds of the present invention can selectively regulate androgen receptor (AR) activity, inhibit AR nuclear transport, thereby blocking the interaction between AR and DNA, and then characterizing the activity against prostate tumor cells. On the other hand, the compounds of the present invention have good AR receptor binding affinity and AR receptor antagonist activity, and can avoid the teratogenicity produced by the thalidomide ligands of CRBN. In addition, this conjecture has been verified by the AR / ARV7 protein degradation activity in in vitro cells.
[0146] Experimental Example 3 AR / ARV7 protein degradation activity test in vitro cells
[0147] LNCaP, 22RV1 or 293V7 cells were added to 6-well plates at a ratio of 500,000 cells per well or approximately 1.5 million cells per 10 cm dish and cultured in RPMI 1640 medium containing 10% FBS for 24 hours. Protein extracts were prepared after LNCaP, 22RV1 or 293V7 cells were treated with compounds for 24 hours. Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Western blot analysis was performed using the following antibodies: anti-AR, anti-ARV7, anti-PSA, anti-β-actin. LNCaP, 22RV1 cells were treated with 10 μM AR88 or AR74 alone or in combination with the proteasome inhibitor MG132 (10 μM or 5 μM), and cells were treated with cycloheximide (50 μM or 30 μM) to block protein synthesis. After 10 hours of treatment, cell lysates were collected and subjected to protein Western blot analysis. The results of AR / ARV7 protein degradation are shown in Figure 3 The results showed that compounds 8 and 10 showed effective AR / ARV7 protein degradation activity in prostate cancer LNCaP and 22RV1 cells, and were concentration-dependent, verifying that the compounds of the present invention can selectively regulate the activity of androgen receptor AR.
[0148] The preferred embodiments of the present invention are described in detail above; however, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, various equivalent transformations can be made to the technical solutions of the present invention, and these equivalent transformations all belong to the protection scope of the present invention.
Claims
1. The use of aryloxycyclohexyl compounds in the preparation of anti-prostate cancer drugs, characterized in that The aryloxycyclohexyl compounds are compound 8 and compound 10, as shown below:
